• If you are wondering whether Corcept Therapeutics stock is still attractively priced after a strong run, the key question now is how its current share price compares with a reasonable view of fair value.
• The stock last closed at US$81.75, with returns of 4.6% over the past week, 48.3% over the past month, 114.0% year to date, 14.8% over the past year, 264.0% over three years, and 267.3% over five years. These figures naturally raise questions about how much of the story might already be reflected in the price.
• Recent headlines around Corcept Therapeutics have focused on its position in the pharmaceuticals space and how investors are responding to its current profile and pipeline potential. This context helps explain why the stock has attracted attention alongside those strong recent return figures.
• On Simply Wall St's valuation checks, Corcept Therapeutics has a value score of 2 out of 6. This sets up a closer look at how different valuation methods assess the stock today and points to an even better way to think about valuation that will be covered at the end of this article.

Corcept Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corcept Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Corcept Therapeutics stock might be worth by projecting future cash flows and discounting them back to today using a required return. The idea is simple: the value of the business is the present value of the cash it could generate for shareholders over time.

For Corcept Therapeutics, the latest twelve month Free Cash Flow (FCF) is about $119.40 million. Using analyst inputs for the next few years and then extending those projections further out, Simply Wall St models Free Cash Flow rising to an estimated $303 million in 2030. The years between 2026 and 2035 are captured in a 2 Stage Free Cash Flow to Equity framework that blends analyst estimates with extrapolated figures.

On this basis, the DCF model produces an estimated intrinsic value of about $83.61 per share. Against the recent share price of $81.75, this implies the stock trades at roughly a 2.2% discount to that estimate, which is very small and well within normal uncertainty around forecasts.

Result: ABOUT RIGHT

Corcept Therapeutics is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Corcept Therapeutics Price vs Sales

For profitable companies like Corcept Therapeutics, price-based multiples are a simple way to see what investors are paying for each dollar of the business. The preferred metric here is the P/S ratio, which compares the company’s market value to its revenue and is especially common for healthcare stocks where earnings can be affected by one-off items.

What investors are willing to pay on a P/S basis tends to rise when growth expectations are higher and perceived risk is lower, and to be lower when growth is modest or risk is higher. Corcept Therapeutics currently trades on a P/S ratio of 11.41x, compared with an industry average of 5.36x and a peer average of 6.14x in the Pharmaceuticals group.

Simply Wall St’s “Fair Ratio” is its own estimate of what the P/S should be, given factors such as earnings growth, profit margin, market cap, industry and specific risks. This is more tailored than a basic peer or industry comparison, which treats all companies as if they had similar prospects and risk profiles. For Corcept Therapeutics, the Fair Ratio is 15.74x, above the current 11.41x. This indicates that the stock is trading below that modelled level.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Corcept Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand what Corcept Therapeutics might be worth. Narratives bring your view of the company’s story together with your own assumptions for future revenue, earnings and margins, link that to a forecast and fair value, and then let you compare that fair value with the current price inside Simply Wall St’s Community page. Narratives update as new news or earnings arrive. For Corcept Therapeutics, one investor might align with the higher end fair value around US$121 based on more optimistic earnings paths, while another might lean closer to US$50 based on a more cautious view. Each of those perspectives becomes a clear, easy-to-track Narrative you can use to inform your own investment decisions.

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.